ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Advisory Group, Other Cancer Meetings

March 31, 1989

In Brief: Lane Adams Retires, Gadberry New Executive VP; Lemaistre ACS President, Loeb President Elect

November 15, 1985

Final Issue of ‘78

December 15, 1978

For A Better View Of Molecular Targets, NCI Project To Draw Pictures Of Cancers.

June 15, 2001

No Controversy Over Cancer Act This Time

May 25, 1990

Prostatectomy Lowers Death Risk Compared to Watchful Waiting

April 29, 2011